Ventures L.P. 5Am Sells 1,718 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Ventures L.P. 5Am sold 1,718 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $6.85, for a total value of $11,768.30. Following the sale, the insider directly owned 2,846,592 shares in the company, valued at approximately $19,499,155.20. This trade represents a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Entrada Therapeutics Trading Down 0.3%

Shares of NASDAQ:TRDA opened at $7.24 on Wednesday. Entrada Therapeutics, Inc. has a 12-month low of $4.93 and a 12-month high of $16.45. The company has a market capitalization of $281.06 million, a PE ratio of -1.81 and a beta of -0.26. The business has a 50 day moving average of $6.85 and a two-hundred day moving average of $9.79.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.11. The business had revenue of $0.88 million for the quarter, compared to analyst estimates of $2.92 million. Entrada Therapeutics had a negative return on equity of 51.22% and a negative net margin of 2,895.05%. Equities research analysts predict that Entrada Therapeutics, Inc. will post -4.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Baker BROS. Advisors LP grew its stake in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after acquiring an additional 206,911 shares during the period. Wellington Management Group LLP raised its position in Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after acquiring an additional 90,339 shares during the period. Millennium Management LLC lifted its holdings in Entrada Therapeutics by 391.2% during the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after purchasing an additional 666,287 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Entrada Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares in the last quarter. Finally, State Street Corp grew its position in shares of Entrada Therapeutics by 2.0% in the fourth quarter. State Street Corp now owns 508,789 shares of the company’s stock valued at $5,230,000 after purchasing an additional 10,174 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TRDA shares. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 8th. Weiss Ratings lowered shares of Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, June 11th. Roth Capital set a $10.00 target price on Entrada Therapeutics in a research report on Friday, May 8th. Finally, Guggenheim dropped their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $17.50.

Entrada Therapeutics News Summary

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional investors increased their holdings during the second quarter, including Geode Capital Management, Invesco, Prudential Financial, American Century and RhumbLine Advisers. Institutional and hedge-fund ownership stands at approximately 86.39%, providing some support for the stock. Analysts’ consensus price target of $17.50 is also well above TRDA’s recent trading level, though the consensus rating is “Hold.”
• Neutral Sentiment: Entrada’s latest reported quarterly results beat expectations on earnings, with a loss of $0.95 per share versus the expected $1.06 loss. However, revenue was only $0.88 million compared with the $2.92 million consensus estimate, highlighting the company’s early-stage biotechnology profile and continuing operating losses.
• Negative Sentiment: Director Kush Parmar and major shareholder Ventures L.P. 5AM disclosed sales of 114,756 shares at an average price of $6.93, worth approximately $795,259. The filings appear to describe the same transaction through related insider reports, rather than two separate sales. The transaction reduced the holder’s reported ownership by 3.87%, leaving roughly 2.85 million shares. Entrada Therapeutics insider sale article
• Negative Sentiment: The same parties also reported sales of 1,718 shares at an average price of $6.85, valued at approximately $11,768. This reduced ownership by just 0.06%, making it relatively minor compared with the larger sale. Entrada Therapeutics insider selling alert

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.